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Abstract
Background: Varenicline, bupropion and nicotine replacement therapy (NRT) are three effective pharmacotherapies
for smoking cessation, but data about their safety in pregnancy are limited. We assessed the risk of adverse
perinatal outcomes and major congenital anomalies associated with the use of these therapies in pregnancy in
Australia.
Methods: Perinatal data for 1,017,731 deliveries (2004 to 2012) in New South Wales and Western Australia were
linked to pharmaceutical dispensing, hospital admission and death records. We identified 97,875 women who
smoked during pregnancy; of those, 233, 330 and 1057 were exposed to bupropion, NRT and varenicline in
pregnancy, respectively. Propensity scores were used to match exposed women to those who were unexposed to
any smoking therapy (1:10 ratio). Propensity scores and gestational age at exposure were used to match
varenicline-exposed to NRT-exposed women (1:1 ratio). Time-dependent Cox proportional hazards models
estimated hazard ratios (HR) with 95% confidence intervals (95% CI) for any adverse perinatal event (a composite of
10 unfavourable maternal and neonatal outcomes) and any major congenital anomaly.
Results: The risk of any adverse perinatal event was not significantly different between bupropion-exposed and
unexposed women (39.2% versus 39.3%, HR 0.93, 95% CI 0.73–1.19) and between NRT-exposed and unexposed
women (44.8% vs 46.3%, HR 1.02, 95% CI 0.84–1.23), but it was significantly lower in women exposed to varenicline
(36.9% vs 40.1%, HR 0.86, 95% CI 0.77–0.97). Varenicline-exposed infants were less likely than unexposed infants to
be born premature (6.5% vs 8.9%, HR 0.72, 95% CI 0.56–0.92), be small for gestational age (11.4% vs 15.4%, HR 0.68,
95% CI 0.56–0.83) and have severe neonatal complications (6.6% vs 8.2%, HR 0.74, 95% CI 0.57–0.96). Among infants
exposed to varenicline in the first trimester, 2.9% had a major congenital anomaly (3.5% in unexposed infants, HR
0.91, 95% CI 0.72–1.15). Varenicline-exposed women were less likely than NRT-exposed women to have an adverse
perinatal event (38.7% vs 51.4%, HR 0.58, 95% CI 0.33–1.05).
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Conclusions: Pregnancy exposure to smoking cessation pharmacotherapies does not appear to be associated with
an increased risk of adverse birth outcomes. Lower risk of adverse birth outcomes in varenicline-exposed
pregnancies is inconsistent with recommendations that NRT be used in preference to varenicline.
Keywords: Adverse outcomes, Australia, Birth defects, Bupropion, Nicotine replacement therapy, Pregnancy,
Smoking cessation pharmacotherapy, Smoking in pregnancy, Varenicline,
Introduction
Smoking cessation in pregnancy reduces the risk of peri-
natal adverse outcomes and has long-term maternal and
child health benefits [1, 2]. However, a substantial pro-
portion of women continue to smoke throughout gesta-
tion [3] and even in subsequent pregnancies despite
having prior poor birth outcomes [4]. This illustrates the
difficulty of quitting for women who have high levels of
nicotine dependence [5], and highlights the need for ef-
fective assistance. Pharmacotherapies for smoking cessa-
tion including varenicline, bupropion and nicotine
replacement therapy (NRT) are more effective than be-
havioural cessation interventions in non-pregnant adults
[6, 7]; however, little is known about their safety and ef-
ficacy in pregnancy [1, 8–10].
Research evidence about pregnancy outcomes associ-
ated with varenicline exposure is limited to uncontrolled
and small studies, including a case series for 24 women
[11, 12] and 89 other cases identified from teratology
counselling and surveillance services [13]. Available data
regarding pregnancy outcomes of bupropion for smok-
ing cessation (i.e. not for depression) are limited to two
small pilot trials (n = 35) [14, 15] and two small observa-
tional studies (n < 140) [16, 17]. Given the lack of robust
evidence regarding their safety, varenicline and bupro-
pion have no therapeutic indications for smoking cessa-
tion in pregnancy [2, 9, 10]. For NRT on the other hand,
there have been trials [1, 18] and large-scale observa-
tional studies [1, 19–21]; however, neither have been
conclusive [1, 18–21]. This is most likely due to poor ad-
herence to NRT [1] and heterogeneity in the NRT prod-
ucts (e.g. patches, gums, lozenges, spray) under
investigation [19–21]. Transdermal NRT releases con-
tinuous doses of nicotine, thus is potentially associated
with greater risk of harm than intermittent doses offered
by oral forms. Clinical guidelines support the use of
NRT during pregnancy only when the expected benefits
outweigh the potential risks [2, 9, 10].
Although NRT clinical trials have been possible, based
on the assumption that NRT is safer than continued
smoking in pregnancy, this has not been the case for
varenicline or bupropion. In the absence of sufficient
evidence, we established the Smoking MUMS (Maternal
Use of Medications and Safety) Study [22], a population-
based cohort study focused on smoking cessation
pharmacotherapies during pregnancy. In this Australian
cohort of women who smoked during pregnancy, 3.6%
used a smoking cessation therapy, mostly varenicline
(1.8%) and NRT (1.7%) [23]. The current paper aimed
to:
1) Compare the risk of adverse perinatal outcomes
and major congenital anomalies between
pregnancies exposed to these pharmacotherapies
and pregnancies exposed to smoking but no
pharmacotherapy and
2) Compare the risk of these outcomes between




The Smoking MUMS Study is a cohort design based on
all pregnancies that resulted in a birth (gestational age ≥
20 weeks or birthweight ≥ 400 g) in two Australian states,
New South Wales (NSW) and Western Australia (WA),
between 2003 and 2012. The study protocol, data
sources and data preparation have been described else-
where [22, 24]. The current analyses used linked records
from four data sources including perinatal data (deliver-
ies in 2003–2012), dispensing data for pharmaceuticals
subsidised through the Pharmaceutical Benefits Scheme
(PBS, 2003–2013), hospital admissions (2001–2013) and
deaths (2003–2014). Under Australian universal health
care system, eligible residents had access to subsidised
prescriptions of bupropion (for smoking cessation only)
from February 2001 and varenicline from January 2008.
Subsidy for NRT patches commenced in December
2008, initially only for Aboriginal and Torres Strait Is-
lander people, and then for the general population since
January 2011. At time of conducting this study, oral
forms of NRT were not subsidised in Australia. All
forms of NRT, including patches, were also available
over the counter whilst bupropion and varenicline were
only available on prescription.
Study population
We identified a base cohort of pregnant women (con-
ception between 1 January 2004 and 9 April 2012) who
smoked during pregnancy. Conception date was
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estimated using the equation: date of conception = date
of delivery − gestational age at delivery × 7 + 14 days
[22]. The beginning and end points of cohort entry en-
sure that dispensing data were available for at least 1 year
prior to conception and deliveries in 2012 did not dis-
proportionately include pregnancies with gestation
shorter than 40 weeks.
Maternal smoking status in pregnancy was derived
from either perinatal or maternal hospital admission
data [25]. During the study period, there were changes
in maternal smoking items in the perinatal data collec-
tions (2010 in WA and 2011 in NSW). Therefore, for
those who delivered before 2010 in WA and before 2011
in NSW, a woman was identified as having smoked dur-
ing pregnancy if the response was Yes to the item about
whether a woman smoked during pregnancy. For those
who delivered in 2010 onwards in WA, smoking status
was defined as Yes if the reported quantity of tobacco
cigarettes smoked each day during the first or the sec-
ond half of pregnancy was greater than 0. For those who
delivered in NSW in 2011 onwards, smoking status was
based on a Yes response to items indicating whether a
woman smoked in the first or the second half of the
pregnancy. Based on the hospital admission correspond-
ing to the delivery [25], a woman was identified as hav-
ing smoked during pregnancy if a Z72.0 code (i.e. use of
tobacco in the last month) [26] was recorded in any
diagnosis field. In addition, some women who were not
identified as having smoked in pregnancy but had dis-
pensing of a smoking cessation therapy during preg-
nancy were reclassified as smokers according to a
published algorithm [23].
From the base cohort above, we identified women who
were exposed to bupropion, varenicline and NRT during
pregnancy and women who had never been exposed to
any of these medicines in pregnancy. As aforementioned,
subsidy for these medicines commenced at different time
points. Accordingly, for comparisons involving bupro-
pion, varenicline and NRT, the study periods started
from 1 January 2004, 1 January 2008 and 1 January
2009, respectively. When comparing outcomes of differ-
ent therapies (aim 2), we required exposure to occur
over the same calendar time to avoid confounding by
the underlying temporal variation in pregnancy and
labour care [27, 28]. As only 30 pregnancies were ex-
posed to bupropion between 2009 and 2012 (when both
varenicline and NRT were available), comparisons be-
tween bupropion and other therapies were not con-
ducted. In accordance with ethical approvals for this
study, congenital anomalies were examined among in-
fants born in NSW only. Cell sizes were such that this
outcome could be examined among only varenicline-
exposed pregnancies relative to pregnancies exposed to
smoking but no pharmacotherapy (Fig. 1).
Exposure to smoking cessation pharmacotherapy
Dispensing data included records of all subsidised vare-
nicline (Anatomical Therapeutic Chemical [ATC] code
N07BA03), NRT patches (N07BA01) and bupropion
(code change from N07BA02 to N06AX12) [29]. The
recommended course for non-pregnant adults is at least
7 weeks for bupropion (150 mg once daily for the first 3
days then 150 mg twice daily), at least 8 weeks for NRT
(one patch daily) and 12 weeks for varenicline (0.5 mg
once daily for the first 3 days then 1mg once daily); one
course generally involves two or more prescriptions [2].
Records of these therapies dispensed in the period from
100 days pre-conception to date of delivery were identi-
fied; the earliest dispensing in this period was referred to
as the index dispensing. Days covered by each dispens-
ing was estimated by dividing the quantity dispensed by
recommended daily dosage. A pregnancy was identified
as exposed if there were one or more dispensings of the
therapy in the gestation period (i.e. conception to deliv-
ery) or pre-conception dispensings were sufficient to last
into the gestation period (i.e. date of the index dispens-
ing + days covered by pre-conception dispensings ≥ date
of conception). Date of exposure was defined as either
(i) date of the index dispensing if dispensed after con-
ception or (ii) date of conception if pre-conception dis-
pensings were sufficient to last into the gestation period
or (iii) date of the first post-conception dispensing if
pre-conception dispensings were insufficient to last into
the gestation period. Gestational age at exposure
(expressed as weeks, the whole number) was calculated
using the formula [gestational age at delivery − (date of
delivery − date of exposure)/7].
Study outcomes
The two primary outcomes of the study were whether a
woman or neonate experienced any adverse perinatal
event at birth and whether the neonate had any major
congenital anomaly. Any adverse perinatal event was a
composite of 10 individual birth outcomes, including
preterm birth (< 37 weeks, medically indicated or spon-
taneous), small for gestational age (SGA, birthweight <
10th percentile sex- and gestational age-specific) [30],
Apgar score at 5 min < 7, admission to neonatal special
care (NSC), severe neonatal morbidity complications
[31], emergency caesarean section, severe maternal mor-
bidity complications [32], preterm premature rupture of
membranes (PPROM), placental abruption and perinatal
death (stillbirth or 28-day neonatal death). These out-
come variables were derived from the perinatal record,
hospital record relating to the mother’s delivery, hospital
record relating to the baby’s birth and mortality data.
Outcomes including SGA, NSC admission, Apgar score
and severe neonatal morbidity complications were
assessed among live births only. The second primary
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outcome was a diagnosis of any major congenital anom-
aly recorded in hospital admissions occurring within 18
months from birth, among live-born babies in NSW. A
detailed description of the study outcome variables is
presented in Additional file 1.
Exclusions
Exclusion criteria included multiple births, conception
within 6 months from the immediate preceding delivery
[33, 34], interstate residents and overseas visitors (likely
incomplete capture of hospital admission and dispensing
data), use of multiple smoking therapies in the same
pregnancy, use of potentially teratogenic medications
during pregnancy (category D and X, according to the
Australian Therapeutic Goods Administration classifica-
tion system) [35], likely data errors (birthweight < 1000 g
whilst gestational age > 38 weeks, birthweight > 5500 g
whilst gestational age < 37 week, based on the Australian
Fig. 1 Flowchart of pregnancies included in the analyses
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birthweight chart) [30] and missing data (mostly due to
geographical area of residence and Apgar score not be-
ing recorded). In the analysis of the major congenital
anomaly outcome, pregnancies linked to anomalies due
to chromosomal malformations, viral infection (e.g. cyto-
megalovirus, rubella) and known exogenous causes were
also excluded. The numbers of excluded pregnancies ac-
cording to exclusion criteria are presented in Fig. 1 and
Additional file 1: Table S1.4.
Statistical analyses
For aim 1 comparisons, among unexposed women,
24.5% had two or more pregnancies; their first preg-
nancy was selected. In the exposed groups, a small num-
ber of women (n < 5) had two pregnancies exposed to
the same therapy; their first exposed pregnancy was se-
lected. In the analyses for aim 2, there was no woman
with a pregnancy exposed to both varenicline and NRT.
Propensity scores were calculated using logistic regres-
sion models in which the outcome variable was exposure
to a smoking cessation therapy and explanatory variables
included state of birth, year of conception, maternal age
at conception, Aboriginal and/or Torres Strait Islander
status, country of birth, marital status, quintiles of socio-
economic disadvantage scores associated with the resi-
dential area [36], geographical remoteness of the resi-
dential area [37], private health insurance, parity,
previous caesarean section, number of hospital admis-
sions in the year prior to conception and pre-existing
maternal morbidities (mental health, chronic airway con-
ditions, diabetes, hypertension, cardiovascular diseases,
epilepsy, chronic renal diseases, thyroid disorders, sub-
stance and alcohol diagnoses, anaemia and coagulation
disorders, the use of steroids, non-steroid anti-
inflammatory drugs and medications for gastro-
oesophageal reflux diseases). For the analysis of congeni-
tal anomalies, the propensity score model included an
additional variable indicating whether the mother had
previously had a child with a major congenital anomaly.
See Additional file 1 for a comprehensive description of
variables included in propensity score models and how
they were derived from the source data.
For analyses addressing aim 1, each exposed pregnancy
was matched to ten unexposed pregnancies on propen-
sity score, using a greedy five- to one-digit algorithm
(matching on the five digits of propensity score first,
then four digits if there was no five-digit match, and so
on to one-digit matching, with no replacement) [38]. To
address aim 2, the matching (1:1 ratio) used both pro-
pensity score and gestational age at exposure. Absolute
standardised differences were calculated to assess bal-
ance in the characteristics of the comparison groups
(balanced if the difference < 0.1) [39]. Cox proportional
hazard modelling (discrete tier for matched data,
gestational week as time scale) was used to estimate haz-
ard ratios (HRs). In these Cox models, exposure was de-
fined as a time-dependent variable, i.e. a pregnancy was
considered unexposed until the gestational week at ex-
posure. The window of exposure was the first trimester
(gestational week at exposure < 13) when examining the
congenital anomaly outcome, up to week 37 (gestational
week at exposure < 37) for the composite adverse peri-
natal event and preterm birth, and until delivery for
other individual perinatal outcomes.
For comparisons addressing aim 1, the matched sam-
ples were well-balanced on maternal characteristics
(Table 1); thus, univariable Cox models were built. For
aim 2 comparisons, multivariable Cox models were built
to adjust for characteristics with a standardised differ-
ence > 0.1 [39]; however, only the multivariable model
assessing the composite perinatal outcome converged.
Therefore, for this composite perinatal outcome, both
univariable and multivariable HRs were reported, and
for individual perinatal outcomes, univariable HRs were
presented.
Given the concern that women might have ceased
therapy when they became aware of their pregnancy, we
conducted sensitivity analyses by restricting the analyses
to women who initiated the therapy after week 4 of ges-
tation. It was only possible to conduct sensitivity ana-
lyses for the composite adverse perinatal event outcome
(see Additional file 2: Table S2.6) because of small sam-
ple sizes for the other individual perinatal outcomes. All
analyses were carried out in SAS version 9.4.
Results
In the Smoking MUMS Study, there were 1,017,731
pregnancies belonging to 686,884 women in NSW and
WA (conception between 1 January 2004 and 9 April
2012). The base cohort included 103,753 women who
smoked in 140,913 pregnancies; of those, 13,667 preg-
nancies were excluded. Following the selection of one
pregnancy per woman, data analyses included 233, 1057
and 330 women who were exposed to bupropion, vareni-
cline and NRT, respectively, and 96,255 unexposed
women (Fig. 1). As presented in Fig. 2, most women had
only one dispensing of a smoking cessation therapy.
Therapy initiation before conception was more common
for bupropion (65.1%) and varenicline (65.6%) than for
NRT (20%).
Table 1 shows that the matching procedures resulted
in well-balanced baseline characteristics between ex-
posed and unexposed pregnancies (see Additional file 2:
Tables S2.1-S2.5 for before-matching characteristics).
Nevertheless, in comparison to NRT-exposed women,
varenicline-exposed women were more likely to be born
overseas, had a partner and a private health insurance
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but were less likely to have a mental health condition
and drug and alcohol disorders.
The analyses of the first primary outcome (Table 2)
showed that the risk of having any adverse perinatal
event was not significantly different between bupropion-
exposed and unexposed pregnancies (hazard ratio [HR]
0.93, 95% confidence interval [CI] 0.73 to 1.19) or be-
tween NRT-exposed and unexposed pregnancies (HR
1.02, 95% CI 0.84 to 1.23). Compared to unexposed
women, there was a lower risk of any adverse perinatal
event in those who were exposed to varenicline (HR
0.86, 95% CI 0.77 to 0.97). When exposure to NRT was
the reference group, exposure to varenicline was not as-
sociated with higher risk of any adverse event (multivari-
able HR 0.58, 95% CI 0.33 to 1.05, univariable HR 0.59,
95% CI 0.38 to 0.91). As presented in Table 3, 2.9% of
infants exposed to varenicline in the first trimester had a
major congenital anomaly compared to 3.5% of infants
Fig. 2 Timing and duration of exposure to a smoking cessation pharmacotherapy in pregnancy. The beginning of each horizontal line indicates
the date of dispensing and the length of the line represents the number of days covered by the dispensing. *LMP last menstrual
period (estimated)
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not exposed to any smoking cessation therapy (HR 0.91,
95% CI 0.72 to 1.15).
Our analyses of individual birth outcomes (Table 2)
also showed that varenicline-exposed women were less
likely than unexposed women to have a baby who was
born preterm (HR 0.72, 95% CI 0.56 to 0.92), was small
for gestational age (HR 0.68, 95% CI 0.56 to 0.83), had
an Apgar score at 5 min less than 7 (HR 0.47, 95% CI
0.27 to 0.81) and had severe morbidity complications
(HR 0.74, 95% CI 0.57 to 0.96). Varenicline-exposed
women were also less likely than NRT-exposed women
to have a preterm birth (HR 0.29, 95% CI 0.12 to 0.71).
In the sensitivity analyses restricted to women who ini-
tiated therapy after week 4 of gestation, there were large
reductions in the number of exposed pregnancies. Haz-
ard ratios for the composite adverse perinatal event were
similar to those of the main analyses; however, the ef-
fects of varenicline (compared to no therapy) became




Overall, our population-based study found significant re-
duction in the risk of any adverse perinatal event associ-
ated with pregnancy exposure to varenicline and no
increased risk of major congenital anomalies associated
with first trimester exposure to varenicline. There was
also no significant increase in risk of any adverse peri-
natal event associated with exposure to bupropion and
NRT. When individual perinatal outcomes were exam-
ined, findings were most encouraging for varenicline
such as a significant reduction in the risk of preterm
birth, SGA and severe neonatal morbidity complications.
Comparison with other studies
This is the first controlled comparison of varenicline ex-
posure in pregnancy; prior studies were not able to draw
a causal relationship [11–13]. Protective effects of vare-
nicline in this study could be potentially explained by it
being the most efficacious pharmacotherapy for smoking
cessation as reported by studies in non-pregnant adults
[40], and the timing of its use. In our study, the majority
of varenicline-exposed pregnancies had the therapy dis-
pensed prior to conception or in the first few weeks of
the first trimester, a pattern that is consistent with the
recommendation that varenicline not be used in preg-
nancy [2, 9, 10]. Early use of varenicline in pregnancy
could have resulted in early quitting in pregnancy. Prior
studies have shown that earlier smoking cessation in
pregnancy is associated with a greater reduction in the
risk of preterm birth [41, 42] and SGA [41, 43]. Whilst
the early use of varenicline may explain why pregnancies
exposed to varenicline had better outcomes than preg-
nancies not exposed to any therapy, superior efficacy of
varenicline in non-pregnant adults compared to NRT
[40] may explain why pregnancies exposed to varenicline
had more favourable outcomes than those exposed to
NRT, because in the varenicline-NRT comparisons,
pregnancies were matched on gestational age at expos-
ure. Within the Smoking MUMS Study, another analysis
is underway to compare the effectiveness of varenicline
and NRT when used in pregnancy.
Our study found that exposure to varenicline in the
first trimester was not associated with increased risk of
any major congenital anomaly. A previous study of vare-
nicline was limited to two cases with congenital anomal-
ies [13]. In our study, the proportion of infants with a
major congenital anomaly (exposed to varenicline or
Table 3 Major congenital anomalies in infants exposed to varenicline in the first trimester and matched comparison group. Data
presented are numbers (percentage) of outcomes and hazard ratios (95% confidence interval)
Varenicline, 1st trimester Unexposed Hazard ratio (95% CI)†
Any major congenital anomaly 20 (2.9%) 242 (3.5%) 0.91 (0.72–1.15)
Genitourinary 7 (1.0%) 67 (1.0%) 1.00 (0.67–1.51)
Cardiovascular 6 (0.9%) 52 (0.7%) 1.16 (0.75–1.79)
Musculoskeletal < 5 57 (0.8%) –
Gastrointestinal < 5 28 (0.4%) –
Nevers < 5 18 (0.3%) –
Respiratory < 5 6 (0.1%) –
Eyes < 5 11 (0.2%) –
Face, neck 0 < 5 –
Integumentary 0 < 5 –
Genetic syndromes < 5 7 (0.1%) –
Situs inversus 0 < 5 –
Others < 5 9 (0.1%) –
†Hazard ratio was obtained from the univariate model
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exposed to smoking but not pharmacotherapy) are con-
sistent with the underlying Australian and international
figures [44–46]. To date, there were no human studies
that have examined the pharmacokinetics of varenicline
in pregnancy. Animal studies found that maternal expos-
ure to high dosage of varenicline was associated with
low foetal weight and development toxicity in offspring
[47]. Studies in rats and rabbits did not find a terato-
genic effect of varenicline, even with administered dos-
ages 23 and 50 times higher, respectively, than the
maximum recommended human daily dose [47]. How-
ever, it has been long established that animal studies are
seriously limited in their ability to predict human terato-
genesis [48, 49].
Overall, this is the most rigorous study to assess safety
of bupropion for smoking cessation in pregnancy. Previ-
ous smaller studies [14–17] were based on self-reported
exposure [16, 17] and were not able to separate bupro-
pion use for smoking cessation from its use for depres-
sion [16, 17]. Our study found a 15% increase in the risk
of emergency caesarean section although this was not
statistically significant. This raised questions about the
biological pathway of bupropion, given that bupropion
and its metabolites can cross the placenta into foetal cir-
culation [50].
The medicinal form of nicotine prevents a foetus from
being exposed to a multitude of toxic substances in
cigarette smoke [2, 9]. As nicotine and cotinine (nico-
tine’s metabolite) pass through the placenta [21, 51],
nicotine obtained through the patches could pose health
risk to the foetus, e.g. disrupted development of foetal
cholinergic system in the first trimester [51]. However,
due to faster clearance of nicotine and cotinine in preg-
nancy [52], effects of NRT would be less profound than
cigarette smoke. Our study found no differences in peri-
natal outcomes between NRT-exposed and unexposed
pregnancies which are generally consistent with reports
from clinical trials [1, 18] and observational studies [19,
20]. A previous study which reported an increased risk
of preterm birth and low birthweight [21] failed to con-
trol for the effect of maternal smoking. Nevertheless, a
clinical trial has showed that high-dose NRT patches
may increase diastolic blood pressure in late pregnancy,
which may potentially lead to unfavourable pregnancy
outcomes [18].
Strengths and limitations of the study
To our knowledge, this is the largest study to date about
the safety of varenicline in pregnancy. We used different
study designs (i.e. non-user and active comparator) to
examine outcomes associated with varenicline use; this
addressed concerns about confounding by indication
and health-seeking behaviours. The use of propensity
score matching also addresses confounding by maternal
characteristics [53]. Exposure was analysed in a time-
dependant manner, eliminating immortal time bias [54].
Reliable recording of date of delivery and gestational age
in perinatal data [55, 56] enabled accurate ascertainment
of pregnancy exposure.
This study has some limitations. The study included
pregnancies delivered at least 20 weeks of gestation; thus,
outcomes such as pregnancy loss or termination before
week 20 were not examined. Our study had inadequate
statistical power to address effects of exposure to bupro-
pion and NRT on rare perinatal adverse outcomes such
as severe maternal morbidity complications, PPROM,
Apgar score at 5 min < 7, placental abruption and peri-
natal mortality. It was not possible for the study to
examine specific major congenital anomalies associated
with first trimester varenicline exposure. Outcomes such
as changes in mood, behaviour or thinking were not ex-
amined in this study. Although the risk of these mental
health side effects associated with varenicline or bupro-
pion use has been found to be less profound than previ-
ously thought, a risk remains in people with a history of
mental illness [57]. In Australia, NRT can be purchased
over the counter, and in geographically remote regions,
clients of Aboriginal Health Services may receive NRT
free of charge without the need for a prescription [58].
Such data were not captured in PBS dispensing data;
thus, some exposed pregnancies would have been classi-
fied as unexposed. Nevertheless, we believe the extent of
misclassification of exposure status would be negligible
due to financial barriers such as low income among a
large proportion of smoking women [59] and high out-
of-pocket costs of NRT purchased over the counter [60].
Although the main analyses in this study assumed that
exposed women took all of the dispensed medicine as
per recommended dosages, this may not be the case and
actual exposure status and periods of exposure may de-
viate from this assumption. A particular concern was
that women might have ceased therapy when they be-
came aware of their pregnancy, but sensitivity analyses
focused on women who initiated therapy after week 4 of
gestation suggest that the study findings are robust.
Conclusions
Given the uncertainty about the safety of varenicline and
bupropion during pregnancy, these therapies are not
recommended in pregnant women. As evidence regard-
ing the safety of NRT during pregnancy is inconsistent,
clinical guidelines place the onus on the physician to de-
cide whether the potential benefits of NRT use during
pregnancy outweigh the risk of harm [2, 9, 10]. As a re-
sult, women and healthcare providers are currently in a
bind when deciding whether a smoking cessation
pharmacotherapy should be used, and if so, which one.
Our study showed that varenicline is being used in
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pregnancy and its benefit is likely to outweigh the harm.
This could help assess whether experimental studies
might be ethical. Further multi-jurisdictional collabora-
tions are needed for more robust evidence, which could
allow investigations of outcomes such as miscarriage,
terminations, specific malformations, maternal cardio-
vascular and neuropsychiatric events, and long-term out-
comes for the babies given concerns about neurological
development [47].
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